Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enzymatica ABOSTO:ENZY -0.27%58 Gross Margin % is 45.32% as of Jun. 2026, which is 27% below its 10-year median of 62.02. GuruFocus rates OSTO:ENZY with a GF Score™ of 58/100 and a GF Value™ of kr2.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 942 Drug Manufacturers companies, Enzymatica AB ranks better than 65.18% on this metric.
The historical rank and industry rank for Enzymatica AB's Gross Margin % or its related term are showing as below:
OSTO:ENZY'
s Gross Margin % Range Over the Past 10 Years
Min: 57.69 Med: 62.02 Max: 73.23
Current: 57.69
During the past 13 years, the highestGross Margin % of Enzymatica AB was 73.23%. The lowest was 57.69%. And the median was 62.02%.
OSTO:ENZY's Gross Margin % is ranked better than 65.18% of 942
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs OSTO:ENZY: 57.69
Enzymatica AB had a gross margin of 45.32% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Enzymatica AB was -0.10% per year.
Enzymatica AB (OSTO:ENZY) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Enzymatica AB had a gross margin of 45.32% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Enzymatica AB Gross Margin % Related Terms
Enzymatica AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Enzymatica AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Enzymatica AB (OSTO:ENZY) has a Gross Margin % of 45.32% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Enzymatica AB and its competitors. This is 27% below median its historical median of 62.02. Over the past decade, Enzymatica AB's Gross Margin % has ranged from 57.69 to 73.23. According to the industry distribution chart, Enzymatica AB ranks #328 out of 942 companies in the Drug Manufacturers industry, placing it in the top 34.8%.
Is Enzymatica AB's Gross Margin % too high?
Enzymatica AB's current Gross Margin % of 45.32% is 27% below median its 10-year median of 62.02. Over the past 10 years, this metric has ranged from a low of 57.69 to a high of 73.23. The Drug Manufacturers industry median Gross Margin % is 48.54. Enzymatica AB's value of 45.32% is 6.6% below this industry median. Based on the distribution chart, Enzymatica AB ranks #328 out of 942 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Enzymatica AB has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #328 out of 942 companies for Gross Margin %. This puts Enzymatica AB in the upper half of its industry. The industry median Gross Margin % is 48.54. Enzymatica AB's value of 45.32% is 6.6% below this benchmark. Historically, Enzymatica AB's own Gross Margin % has ranged from 57.69 to 73.23 over the past decade. While the company's 10-year median is 62.02 vs. the industry median of 48.54, Enzymatica AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enzymatica AB's current Gross Margin % of 45.32% is 6.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Enzymatica AB and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current Gross Margin % is 45.32%, which is 27% below median its own 10-year median of 62.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (OSTO:ENZY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2.13, compared to a current price of kr1.85 — trading 13.4% below its estimated fair value. The current Gross Margin % is 45.32%, which is 27% below median its 10-year median of 62.02 and 6.6% below the Drug Manufacturers industry median of 48.54. Enzymatica AB's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Enzymatica AB (OSTO:ENZY), the current Gross Margin % is 45.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (OSTO:ENZY) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be undervalued.
The current stock price of kr1.85 is trading 13.4% below its estimated GF Value™ of kr2.13.
GuruFocus considers Enzymatica AB to be Modestly Undervalued.
Key valuation signals for OSTO:ENZY:
Gross Margin %: 45.32% (27% below median its 10-year median of 62.02)
GF Value™: kr2.13 vs. price of kr1.85 (13.4% below fair value)
Industry Position: 6.6% below the Drug Manufacturers median (#328 of 942)
No single metric tells the full story. See the OSTO:ENZY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
58GF Score
Get the complete analysis for OSTO:ENZY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ENZY has been successfully added to your 
